Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Patent
1996-03-29
1998-02-10
Shah, Mukund J.
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
544360, 546193, 546194, 546207, 546208, 546213, 546226, 546227, C07D21106, C07D21136, C07D21160
Patent
active
057170924
ABSTRACT:
The present invention relates to compounds that can maintain, increase, or restore sensitivity of cells to therapeutic or prophylactic agents. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well-suited for treatment of multi-drug resistant cells, for prevention of the development of multi-drug resistance, and for use in multi-drug resistant cancer therapy.
REFERENCES:
patent: 4920218 (1990-04-01), Askin
patent: 5192773 (1993-03-01), Armistead
patent: 5330993 (1994-07-01), Armistead
G. Blaschke et. al., "Investigation of Chromatographic Resolutions of Racemates. VI. Polymeric Amino Acid Derivatives As Optically Active Adsorbents," Chem. Ber., 109(6), pp. 1967-1975 (1976).
D. Boesch et. al., "In Vivo Circumvention of P-Glycoprotein-Mediated Multidrug Resistance of Tumor Cells with SDZ PSC 833," Cancer Res., 51, pp. 4226-4233 (1991).
A.M. Cameron et. al., "Immunophilin FK506 Binding Protein Associated With Inositol 1,4,5-Trisphosphate Receptor Modulates Calcium Flux," Proc. Natl. Acad. Sci. USA., 92, pp. 1784-1788 (Feb., 1995).
A.M. Cameron et al., "Calcineurin Associated with the Inositol 1,4,5-Trisphosphate Receptor-FKBP12 Complex Modulates Ca.sup.2+ Flux," Cell 83, pp. 463-472 (Nov., 1995).
R. S. Coleman et. al., "Degradation and Manipulations of the Immunosuppressant FK506: Preparation of Potential Synthetic Intermediates," Heterocycles, 28, pp. 157-161 (1989).
M. Egbertson and S.J. Danishefsky, "Synthetic Route to the `Tricarbonyl` Region of FK-506," J.Org. Chem. 54, pp. 11-12 (1989).
B.G. Gold et al., "FK506, an Immunosuppressant, Increases Functional Recovery and Axonal Regeneration in the Rat Following Axotomy of the Sciatic Nerve," Soc. Neurosci. Abs., 19, p. 1316 (1993).
B.G. Gold, et al., "The Immunosuppressant FK506 Increases the Rate of Axonal Regeneration in Rat Sciatic Nerve," Journal of Neuroscience, 15, pp. 7509-7516 (Nov., 1995).
M.T. Goulet and J. Boger, "Degradative Studies on the Tricarbonyl Containing Macrolide Rapamycin", Tetrahedron Lett., 31, pp. 4845-4848 (1990).
W.N. Hait et. al., "Activity of Cyclosporin A and a Non-Immunosuppressive Cyclosporin Against Multidrug Resistant Leukemic Cell Lines", Cancer Commun., 1(1), pp. 35-43 (1989).
M.W. Harding et. al., "A Receptor for the Immunosuppressant FK-506 is a Cis-Trans Peptidyl-Prolyl Isomerase", Nature, 341, pp. 758-760 (1989).
J.R. Hauske et al., "Design and Synthesis of Novel FKBP inhibitors," J. Med. Chem., 35, pp. 4284-4296 (1992).
J.R. Hauske et. al., "Investigation of the Effects of Synthetic, Non-Cytotoxic Immunophilin Inhibitors of MDR", Bioorg. & Med. Chem. Lett., 4, pp. 2097-2102 (1994).
W.E. Lyons et al., "Immunosuppressant FK506 Promotes Neurite Outgrowth in Cultures of PC12 Cells and Sensory Ganglia," Proc. Natl. Acad. Sci. USA, 91, pp. 3191-3195 (1994).
W.E. Lyons et al., "Neuronal Regeneration Enhances the Expression of the Immunophilin FKBP-12," J. Neuroscience., 15, pp. 2985-2994 (Apr., 1995).
J. Sharkey and S.P. Butcher, "Immunophilins Mediate the Neuroprotective Effects of FK506 in Focal Cerebral Ischaemia," Nature, 371, pp. 336-339 (1994).
K. Soai et. al., "Diastereoselective Reduction of Chiral Alpha-Ketoamides Derived from (S)-Proline Esters with Sodium Borohydride," J. Chem. Soc. Perkin Trans. 1, pp. 769-772 (1985).
J. Steiner, "Neuroimmunophilins and Nerve Regrowth," Cambridge Healthtech Institute's Alzheimer's Disease: The Promise of New Therapeutics, Jun. 8, 1995--Jun. 9, 1995.
Armistead David M.
Saunders Jeffrey O.
Haley, Jr. James F.
Marks Andrew S.
Rao Deepak R.
Shah Mukund J.
Vertex Pharmaceuticals Inc.
LandOfFree
Compounds with improved multi-drug resistance activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds with improved multi-drug resistance activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds with improved multi-drug resistance activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2078367